HCC Surveillance Saves Lives: Frontline Gastroenterology | July 2026

Introduction:

Hepatocellular carcinoma (HCC) surveillance enables earlier diagnosis and improves survival. This largest UK multicenter study evaluated how patients are diagnosed in routine clinical practice and identified major gaps in the surveillance pathway.

Why was this study needed?

• Early HCC detection remains suboptimal despite established surveillance guidelines.
• Real-world data on surveillance performance across the UK have been limited.
• Understanding where surveillance fails is essential to improve outcomes.
• Earlier diagnosis increases eligibility for curative treatment.
• Better surveillance pathways could reduce HCC-related mortality.

Results:

• Only 28% of HCC cases were detected through surveillance, while nearly half of patients presented with symptoms, reflecting missed opportunities for early diagnosis.
• Surveillance identified smaller tumors at an earlier stage, resulting in substantially lower 1-year mortality compared with incidental or symptomatic presentation.
• Failures occurred throughout the surveillance pathway, including missed cirrhosis diagnosis, failure to enroll eligible patients, and inadequate surveillance delivery.

Clinical Impact:

This study highlights that the greatest opportunity to improve HCC outcomes lies before the cancer develops—by identifying patients with cirrhosis, enrolling them into surveillance programs, and ensuring regular high-quality follow-up. Strengthening every step of the surveillance pathway could substantially increase early detection and access to curative therapies.

Bottom Line:

HCC surveillance works—but it is underutilized. Fewer than 1 in 3 high-risk patients are diagnosed through surveillance, despite clear evidence that earlier detection saves lives. Improving surveillance implementation should be a major priority in HCC care.